DEXCOM INC
Dexcom, Inc. is a medical device company primarily focused on designing, developing, and commercializing continuous glucose monitoring (CGM) systems for diabetes management. The company's flagship product, the Dexcom G6, received FDA approval in 2018 and is an integrated CGM system (iCGM) that allows for real-time glucose readings and communication with other compatible devices. The G6 has features such as finger stick elimination, easy sensor application, and extended 10-day disposable sensors. In December 2022, the company obtained FDA marketing authorization for the Dexcom G7, which is the most accurate CGM cleared by the FDA and has a smaller, all-in-one wearable design. The company is also working on regulatory approvals for Dexcom Stelo, a product designed for people with Type 2 diabetes who do not use insulin, and Dexcom ONE, a CGM system with a receiver or mobile app. Dexcom's business strategy includes collaborations with insulin delivery systems and organizations for the treatment of Type 2 diabetes. The company's website is dexcom.com, and its stock ticker is DXCM.